Secretary Li Li of the National Medical Products Administration Visits Maixin for Research and Guidance

Secretary Li also inquired in detail about the difficulties and pain points Maxin has encountered in its innovation process, encouraging us to “not fear difficulties and be brave in facing challenges.” He emphasized that when encountering problems, we should communicate more with regulatory authorities, as the goal is to build a good communication platform between regulators and enterprises. While understanding the needs of enterprises, we should create a favorable atmosphere and conditions for enterprise innovation in terms of systems.

The（CMDE）Sun Leidirector, who accompanied the research visit, also fully affirmed Maxin’s efforts in product compliance, stating that the reform of the evaluation and approval system for medical devices requires the joint participation of medical device production and operation enterprises, in order tofurther improve the management of in vitro diagnostic reagents,hope that Maxin, as a representative of pathological IVD enterprises, will actively offer suggestions and ideas, toconsolidate a long-term evaluation management mechanism, and also provide reference for the long-term operation of scientific regulatory concepts at the practical level.

With ample rain, the high fields turn white; wearing a raincoat, they plow at midnight. For over twenty years, Maxin has endured the hardships of its startup phase, firmly believing that only by adhering to high-quality product standards has it achieved the “Maxin Quality” recognized by pathology peers today. In the future, we will continue as always, while upholding quality, strive for innovation, shoulder the burden of a national enterprise, and work tirelessly to better serve China’s pathology professionals.